Unknown

Dataset Information

0

The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor.

ABSTRACT: In acute myeloid leukemia (AML), the Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes. Recently, a new and recurrent juxtamembrane deletion mutation (p.Q569Vfs*2) resulting in a truncated receptor was identified. The mutated receptor is expressed on the cell surface and still binds its ligand but loses the ability to activate ERK signaling. FLT3 p.Q569fs-expressing Ba/F3 cells show no proliferation after ligand stimulation. Furthermore, coexpressed with the FLT3 wild-type (WT) receptor, the truncated receptor suppresses stimulation and activation of the WT receptor. Thus, FLT3 p.Q569Vfs*2, to our knowledge, is the first FLT3 mutation with a dominant negative effect on the WT receptor.

SUBMITTER: Sandhofer N 

PROVIDER: S-EPMC4921855 | biostudies-other | 2016

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor.

Sandhöfer Nadine N   Bauer Julia J   Reiter Katrin K   Dufour Annika A   Rothenberg Maja M   Konstandin Nikola P NP   Zellmeier Evelyn E   Tizazu Belay B   Greif Philipp A PA   Metzeler Klaus H KH   Hiddemann Wolfgang W   Polzer Harald H   Spiekermann Karsten K  

Scientific reports 20160627

In acute myeloid leukemia (AML), the Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes. Recently, a new and recurrent juxtamembrane deletion mutation (p.Q569Vfs*2) resulting in a truncated receptor was identified. The mutated receptor is expressed on the cell surface and still binds its ligand but loses the ability to activate ERK signaling. FLT3 p.Q569fs-expressing Ba/F3 cells show no proliferation after ligand stimulation. Furthermore, coexpressed with the FLT3 wild  ...[more]